Yu Hua Feng

US Patent:

7151087, Dec 19, 2006

Filed:

Oct 31, 2003

Appl. No.:

10/700313

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward A. Berger - Rockville MD, US
Philip M. Murphy - Rockville MD, US
Christopher C. Broder - Rockville MD, US
Paul E. Kennedy - Silver Spring MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Resources - Washington DC

International Classification:

A61K 38/00

US Classification:

514 13, 514 14

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

20030039955, Feb 27, 2003

Filed:

May 10, 2001

Appl. No.:

09/853745

Inventors:

Yu Feng - San Diego CA, US
Hengli Tang - Carlsbad CA, US

International Classification:

C12N007/00
C07H021/04
C12N015/86
C12N015/867
C12N015/863
C12Q001/70
C12N007/01
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74

US Classification:

435/005000, 435/235100, 435/320100, 435/456000, 536/023720

Abstract:

The invention provides methods to produce RNA viral sequences, recombinant RNA viruses, mutants of RNA viruses and RNA virus-derived vectors in cell culture and in vitro using non-viable, replication defective, helper vaccinia recombinants. These methods allow generation of RNA virus sequences and viral particles in cell culture and in vitro independent of their natural replication pathways, bypassing the limitation of any cellular barriers. The invention also provides novel RNA viral sequences and viral particles using these methods.

US Patent:

20070087990, Apr 19, 2007

Filed:

Nov 7, 2006

Appl. No.:

11/594375

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward Berger - Rockville MD, US
Philip Murphy - Rockville MD, US
Christopher Broder - Rockville MD, US
Paul Kennedy - Silver Spring MD, US

International Classification:

A61K 31/70
C12P 21/06
A01N 43/04

US Classification:

514044000, 435069100

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

20080241167, Oct 2, 2008

Filed:

Mar 7, 2008

Appl. No.:

12/044845

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward A. Berger - Rockville MD, US
Philip M. Murphy - Rockville MD, US
Christopher C. Broder - Rockville MD, US
Paul E. Kennedy - Silver Spring MD, US

International Classification:

A61K 39/395
C12N 5/06
G01N 33/566
G01N 33/53
C12Q 1/70
C12Q 1/02
A61K 31/7052
C12N 15/87
A61P 31/18

US Classification:

4241721, 435375, 436501, 435 72, 435 5, 435 29, 514 44, 435440

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

59395389, Aug 17, 1999

Filed:

Dec 19, 1996

Appl. No.:

8/770235

Inventors:

Markley C. Leavitt - La Jolla CA
Richard Tritz - San Diego CA
Yu Feng - San Diego CA
Jack Barber - San Diego CA
Mang Yu - San Diego CA

Assignee:

Immusol Incorporated - San Diego CA

International Classification:

C07H 2102

US Classification:

536 231

Abstract:

Methods of inhibiting HIV infection by blocking HIV co-receptor RNA expression are provided. Ribozymes which cleave HIV co-receptor RNA and inhibit HIV infection of cells are also provided. Co-receptor targets include fusin and CKR5.

US Patent:

20220289806, Sep 15, 2022

Filed:

Aug 11, 2020

Appl. No.:

17/634022

Inventors:

- San Diego CA, US
Haining HUANG - San Diego CA, US
YU FENG - San Diego CA, US
GUILIANA MOGNOL - San Diego CA, US
CAN JIN - San Diego CA, US
DIANA GUIMET - San Diego CA, US

International Classification:

C07K 14/55
C12N 5/0783
A61K 47/02
A61K 47/54
A61K 47/42
A61P 35/00

Abstract:

This disclosure relates to modified interleukin 2 (IL-2) polypeptides, polynucleotides, e.g., DNA, RNA or viral vector, that encode the modified IL-2 polypeptides and are configured to express said modified IL-2 polypeptides in vitro and/or in vivo, conjugates comprising the modified IL-2 polypeptides, and uses thereof.

US Patent:

20210386734, Dec 16, 2021

Filed:

Aug 25, 2021

Appl. No.:

17/412102

Inventors:

- San Diego CA, US
Justin S. Cisar - San Diego CA, US
Katharine K. Duncan - San Diego CA, US
Yu Feng - San Diego CA, US
John J.M. Wiener - La Jolla CA, US
Olivia D. Weber - San Diego CA, US

International Classification:

A61K 31/496
A61P 25/04
A61K 31/506

Abstract:

Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.

US Patent:

20190282568, Sep 19, 2019

Filed:

Jun 4, 2019

Appl. No.:

16/431632

Inventors:

- San Diego CA, US
Justin S. Cisar - San Diego CA, US
Katharine K. Duncan - San Diego CA, US
Yu Feng - San Diego CA, US
John J.M. Wiener - La Jolla CA, US
Olivia D. Weber - San Diego CA, US

International Classification:

A61K 31/496
A61K 31/506
A61P 25/04

Abstract:

Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.